ARQT News and Press, Arcutis Biotherapeutics Inc. From 11/03/23

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

Arcutis Biotherapeutics Inc. (ARQT) is expected to report $-0.9 for Q3 2023

2023-10-26 19:20:36 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Arcutis announces pricing of $100 million public offering ...

2023-10-26 08:35:12 ET More on Golden Minerals, Opendoor Technologies, etc. Opendoor Technologies Inc. (OPEN) Goldman Sachs 2023 Communacopia & Technology Conference Transcript Opendoor: The Bottom May Be Here For The Brave Rentokil Initial: Thriving Compounder I...

WESTLAKE VILLAGE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 8:30 a.m. ET o...

2023-10-20 10:06:59 ET More on Health Care: Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the...

2023-10-20 08:43:02 ET Losers: WeBuy Global Ltd ( WBUY ) -33% . Solaredge Technologies ( SEDG ) -30% posts big miss on preliminary Q3 sales . Alpine 4 Holdings ( ALPP ) -19% . Arcutis Biotherapeutics ( ARQT ) -19% announces pricing of ...

Individual patient response data highlights 95% of individuals treated with ZORYVE had a measurable improvement in Psoriasis Area and Severity Index (PASI) at Week 8 Over 85% achieved measurable improvement by Week 2 (the earliest timepoint measured) Separately reported new data confirms ...

2023-10-20 06:10:30 ET Arcutis Biotherapeutics ( NASDAQ: ARQT ) is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,500,000 shares of common stock in the offering. The shares of common stock are bein...

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritt...